CONMED (NYSE:CNMD) Price Target Lowered to $40.00 at JPMorgan Chase & Co.

CONMED (NYSE:CNMD) had its price target cut by JPMorgan Chase & Co. from $43.00 to $40.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a neutral rating on the stock.

Other analysts have also issued research reports about the stock. Wells Fargo & Company upgraded shares of CONMED to a “hold” rating in a research note on Wednesday, March 18th. Weiss Ratings restated a “sell (d+)” rating on shares of CONMED in a research note on Wednesday, January 21st. Zacks Research upgraded shares of CONMED from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Needham & Company LLC restated a “hold” rating on shares of CONMED in a research note on Thursday, January 29th. Finally, Piper Sandler lowered shares of CONMED from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $55.00 to $39.00 in a research note on Tuesday, March 17th. Six investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, CONMED has a consensus rating of “Reduce” and an average price target of $46.80.

CONMED Stock Up 1.9%

CONMED stock opened at $36.63 on Thursday. The company has a market capitalization of $1.10 billion, a PE ratio of 20.69, a PEG ratio of 1.58 and a beta of 0.99. The firm’s fifty day moving average is $38.63 and its 200 day moving average is $41.13. The company has a quick ratio of 1.01, a current ratio of 2.14 and a debt-to-equity ratio of 0.81. CONMED has a 12-month low of $33.21 and a 12-month high of $61.08.

CONMED (NYSE:CNMD) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The business had revenue of $317.05 million during the quarter, compared to analyst estimates of $310.64 million. CONMED had a net margin of 4.00% and a return on equity of 13.85%. CONMED’s quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.95 EPS. As a group, sell-side analysts predict that CONMED will post 4.36 EPS for the current fiscal year.

Institutional Trading of CONMED

Several institutional investors have recently made changes to their positions in CNMD. AQR Capital Management LLC grew its stake in shares of CONMED by 19.9% in the 1st quarter. AQR Capital Management LLC now owns 14,199 shares of the company’s stock worth $857,000 after acquiring an additional 2,357 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of CONMED by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,354 shares of the company’s stock worth $1,108,000 after acquiring an additional 800 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of CONMED by 5.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 82,686 shares of the company’s stock worth $4,993,000 after acquiring an additional 4,565 shares in the last quarter. Intech Investment Management LLC grew its stake in shares of CONMED by 34.6% in the 1st quarter. Intech Investment Management LLC now owns 22,505 shares of the company’s stock worth $1,359,000 after acquiring an additional 5,780 shares in the last quarter. Finally, Creative Planning bought a new stake in shares of CONMED in the 2nd quarter worth $310,000.

Trending Headlines about CONMED

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q1 results beat expectations — CONMED reported EPS of $0.89 and revenue of $317.05M, topping consensus and showing operating resilience despite a modest topline decline. This beat underpins the stock lift. CONMED Corporation Announces First Quarter 2026 Financial Results
• Positive Sentiment: Management raised 2026 organic growth expectations and signaled strategic sharpening — CONMED now projects 2026 organic growth of ~5.0%–6.5% while refinancing debt and exiting certain GI products to focus on higher-growth surgical segments; that repositioning supports margin and growth expectations longer term. Conmed projects 2026 organic growth of 5.0% to 6.5% while refinancing debt and exiting GI
• Positive Sentiment: Analyst coverage notes the beat and improved organic-sales outlook — independent write-ups highlight the quarter beat and the strategic shift toward higher-growth categories as positives for medium-term revenue mix and profit potential. CONMED’s Q1 Earnings and Revenues Beat, Organic Sales Outlook Up
• Neutral Sentiment: Full earnings call details and slide deck are available for investors reviewing guideposts and management commentary on execution and capital allocation. Use the transcript/slide deck to assess the conviction behind the strategy shift. Q1 Slide Deck / Press Release
• Negative Sentiment: JPMorgan cut its price target to $40 (from $43) and set a neutral rating — a downgrade that can temper short-term upside and analyst-driven demand. Benzinga
• Negative Sentiment: Near-term revenue headwinds from portfolio pruning — CONMED disclosed a ~$15.5M sales reduction from exiting certain GI products and domestic sales down ~5.8% year-over-year, contributing to a modest reported revenue decline and adding near-term growth drag. CONMED Corporation Announces First Quarter 2026 Financial Results

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.